May 21 (Reuters) - AstraZeneca's COVID-19 vaccine
was only slightly less effective against the variant first found
in India than the strain identified in Kent, the company's Chief
Executive Officer Pascal Soriot said in an interview with
Financial Times on Friday.
He added the company is in talks with governments, including
the United Kingdom, about new contracts for booster doses.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Chris